Article

Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients

2021-12-21

Abstract excerpt

<h4>Importance</h4> The SARS-CoV-2 variant Omicron escapes neutralizing antibody responses elicited after COVID-19 vaccination, while T-cell responses might be better conserved. It is crucial to assess how a third dose of vaccination modifies these responses, particularly for immunocompromised patients with readily impaired antibody responses. <h4>Objective</h4> To determine T-cell responses to the Spike (S)-prote...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0d72abff-0410-555d-906d-d5efb78e235c
DOI: 10.1101/2021.12.20.21268128

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patientsDOI 10.1101/2021.12.20.21268128Read

Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapySemantic proximity Read

Response to COVID-19 booster vaccinations in seronegative people with MSSemantic proximity Read

Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinationsSemantic proximity Read

Post-vaccination T cell immunity to omicronSemantic proximity Read

Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapySemantic proximity Read

Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapySemantic proximity Read

Assessment of T-cell Reactivity to the SARS-CoV-2 Omicron Variant by Immunized IndividualsSemantic proximity Read

Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapySemantic proximity Read

SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumabSemantic proximity Read

T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine.Semantic proximity Read

Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 OmicronSemantic proximity Read

Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunitySemantic proximity Read